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5-Fluorouracil (5-FU)-based chemotherapy is frequently associated with diarrhoea. We compared two 5-FU-based regimens and the
effect of Lactobacillus and fibre supplementation on treatment tolerability. Patients diagnosed with colorectal cancer (n¼150) were
randomly allocated to receive monthly 5-FU and leucovorin bolus injections (the Mayo regimen) or a bimonthly 5-FU bolus plus
continuous infusion (the simplified de Gramont regimen) for 24 weeks as postoperative adjuvant therapy. On the basis of random
allocation, the study participants did or did not receive Lactobacillus rhamnosus GG supplementation (1–2 10
10 per day) and fibre
(11g guar gum per day) during chemotherapy. Patients who received Lactobacillus had less grade 3 or 4 diarrhoea (22 vs 37%,
P¼0.027), reported less abdominal discomfort, needed less hospital care and had fewer chemotherapy dose reductions due to
bowel toxicity. No Lactobacillus-related toxicity was detected. Guar gum supplementation had no influence on chemotherapy
tolerability. The simplified de Gramont regimen was associated with fewer grade 3 or 4 adverse effects than the Mayo regimen (45 vs
89%), and with less diarrhoea. We conclude that Lactobacillus GG supplementation is well tolerated and may reduce the frequency of
severe diarrhoea and abdominal discomfort related to 5-FU-based chemotherapy.
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Colorectal cancer is globally the third most common type of cancer
and the fourth most common cause of cancer death (Parkin et al,
1999; Pisani et al, 1999). Curative surgery is feasible in three-
quarters of the patients, but despite this, about one half of
the patients subsequently develop incurable recurrent cancer
(Galandiuk et al, 1992). Adjuvant chemotherapy or chemoradiation
reduces recurrences and mortality in colorectal cancer (Van
Cutsem et al, 2002). Regimens containing 5-fluorouracil (5-FU)
and leucovorin (LV) have been considered as standard adjuvant
chemotherapy regimens in colorectal cancer (O’Connell et al, 1998;
Wolmark et al, 1999; Kerr, 2001), and addition of oxaliplatin to
5-FU and LV appears to further improve efficacy (Andre et al, 2004).
Diarrhoea is one of the most troublesome adverse effects related
to cancer chemotherapy. 5-Fluorouracil-, capecitabine-, and
irinotecan-based regimens that are commonly used in the
treatment of colorectal cancer are frequently associated with
diarrhoea. Excessive bowel motility may be reduced using drugs
such as loperamide and somatostatin analogues, but these
treatments may also be associated with adverse effects, and simple
and safe measures to reduce drug-induced diarrhoea are thus
needed. The mode of chemotherapy administration may also
influence chemotherapy-related toxicity. Regimens where 5-FU is
administered as protracted continuous infusions may result in a
more favourable toxicity profile including the frequency and
severity of diarrhoea as compared to the Mayo regimen, where
5-FU is given as boluses on 5 consecutive days 4-weekly (de Gramont
et al, 1997a).
According to a meta-analysis of controlled trials performed on
hospitalised children who have acute diarrhoea, co-administration
of some microorganisms (probiotics) such as Lactobacillus
rhamnosus GG with standard rehydration therapy reduces the
duration of diarrhoea (Huang et al, 2002). Some placebo-
controlled studies also suggest that probiotics are of benefit in
the treatment of antibiotics-associated diarrhoea and in the
prevention of nosocomial diarrhoea in infants (Szajewska et al,
2001; Cremonini et al, 2002). The putative mechanisms of
L. rhamnosus GG action may include stimulation of the cell
proliferation rate of bowel epithelial cells, enhanced secretion of
protective mucins leading to reduced adherence of enteropatho-
genic bacteria to the bowel wall, inhibition of bacterial trans-
location into the tissues, and stimulation of local and systemic
immune response to pathogens (Mattar et al, 2001; Banasaz et al,
2002; Khaled et al, 2003; Mack et al, 2003; Vaarala, 2003). Partially
hydrolysed guar gum fibre may also reduce duration of diarrhoea
(Homann et al, 1994; Alam et al, 2000) and prolong the colonic
transit time (Meier et al, 1993). Thus, hypothetically, besides the
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smode of 5-FU administration, the frequency and severity of
chemotherapy-associated gastrointestinal adverse events might be
influenced by the diet and the bowel microbial flora.
Three studies have suggested that Lactobacillus acidophilus, L.
rhamnosus, or a probiotic mixture may prevent radiotherapy-
induced diarrhoea (Salminen et al, 1988; Urbancsek et al, 2001;
Delia et al, 2002), but to our knowledge no controlled study has
evaluated probiotics or fibre in the prevention of chemotherapy-
associated diarrhoea. In the present study, we assessed the efficacy
of L. rhamnosus GG and guar gum supplementation in reducing
5-FU-based chemotherapy toxicity. We also compared the toler-
ability and the frequency of diarrhoea related to the Mayo regimen
to that of the simplified de Gramont regimen, which uses a bolus
plus continuous 5-FU infusion.
METHODS
Study design and accrual
The primary end point of this open-label, prospective, rando-
mised, phase III, single institution, 2 3 factorial design study was
the frequency of severe diarrhoea. The study participants had
either Dukes’ B or C colorectal cancer (n¼126) or metastatic
colorectal cancer that had been rendered free from all overt
metastases by surgery (Dukes’ D, n¼24). All patients received
adjuvant chemotherapy following surgery. Chemotherapy con-
sisted either of the Mayo regimen or the simplified de Gramont
regimen, and was administered based on random allocation. In
addition, study participants diagnosed with rectal cancer received
locoregional radiotherapy whenever the caudal tumour margin was
below the distal peritoneal fold.
One hundred and fifty-four subjects were assessed for the study
between November 1997 and August 2001. Of these, one was
ineligible due to age and three others preferred not to participate
leaving a total of 150 eligible patients who consented to participate
in the study. An Institutional Review Board at Helsinki University
Central Hospital approved the study protocol prior to initiation of
the study. A written informed consent was required from the
participants prior to study entry.
Treatment assignment
Allocation to the study treatments was performed using a
computerised minimisation technique (Pocock and Simon, 1975;
Freedman and White, 1976) and one out of six chances. The
patients were randomly allocated at a 1:1 ratio to receive either the
simplified de Gramont regimen or the Mayo regimen as adjuvant
chemotherapy. The participants were also randomly assigned to
receive or not to receive at a 2:1 ratio L. rhamnosus GG and at a
1:2 ratio fibre-containing nutritional support (guar gum). The
allocation group was concealed until interventions had been
assigned. The patients were stratified by gender, tumour site
(colon or rectum), and the Dukes’ stage at randomisation.
Participant eligibility
Subjects were eligible for inclusion provided that age at
randomisation was 18 or higher and 75 or lower, histologically
confirmed colorectal cancer had been removed at surgery, no
metastases were found in staging examinations that included
ultrasound or computed tomography (CT) of the abdomen
and chest X ray or CT of the thorax, and the World
Health Organization (WHO) performance status was two or less.
The study participants were also required to have adequate
bone marrow, kidney, and liver functions for chemotherapy.
Exclusion criteria included other invasive cancer beside colorectal
cancer in history except for carcinoma in situ of the cervix or
nonmelanoma skin cancer; metabolic, neurological, or psychiatric
disease that was incompatible with chemotherapy; a serious
thromboembolic event under active treatment; and pregnancy,
lactation, or absence of adequate contraception in potentially
fertile patients.
Adjuvant systemic chemotherapy and radiation therapy
The Mayo regimen consisted of a short intravenous infusion
of LV 20mgm
 2 (or 10mgm
 2 levoleucovorin) and 5-FU
370–425mgm
 2 administered as an intravenous bolus over
3–5min on days 1–5 of the cycle, which was repeated at 4-week
intervals for six times. The overall duration of chemotherapy was
thus 24 weeks.
The simplified de Gramont regimen consisted of a 2-h infusion
of LV 400mgm
 2 (or 200mgm
 2 levoleucovorin) followed by
5-FU 400mgm
 2 administered as an intravenous bolus and 48-h
infusion of 3.0–3.6gm
 2 5-FU; this cycle was repeated every 14
days for 12 times. The overall duration of chemotherapy was thus
24 weeks (de Gramont et al, 1997b).
Pelvic radiation therapy for rectal cancer was given from three
or four portals using high-energy photons obtained from a linear
accelerator (n¼39). Radiotherapy, based on CT planning, was
administered to a total cumulative dose of 50.4Gy in 1.8Gy
daily fractions over 5.5 weeks except for patients who underwent
abdominoperineal resection, when the dose was limited to 45Gy
to decrease the likelihood of small bowel radiation injury
(n¼8). Leucovorin was omitted during pelvic radiotherapy (cycles
three and four) in rectal cancer patients assigned to receive
the Mayo regimen, and bolus 5-FU, 500mgm
 2, was given only
for 3 days during these cycles. Similarly, rectal cancer patients
assigned to receive the simplified de Gramont regimen did
not receive LV during pelvic radiotherapy (cycles five to
eight) and were treated with continuous 5-FU infusion alone,
225mgm
 2 per day (O’Connell et al, 1994). Seven rectal cancer
patients were treated to a cumulative target dose of 25Gy given as
five equal fractions over 5 consecutive days preoperatively
(Anonymous, 1996; Kapiteijn et al, 2001); no concomitant 5-FU
was given to these patients during radiation, and their post-
operative systemic chemotherapy was given as for colon cancer
patients.
Dietary supplementation
Lactobacillus rhamnosus GG (ATCC 53103, Gefilus
s, Valio Ltd,
Helsinki, Finland) was administered orally as gelatine capsules
twice daily at a dose of 1–2 10
10 per day during the 24 weeks of
adjuvant cancer chemotherapy. Lactobacillus capsules were
swallowed as such, or the capsule content was dissolved in cold
milk or juice. Guar gum containing nutritional supplement
(500ml, Novasource GI control
s, Novartis Nutrition, Basel,
Switzerland (contains 11g guar gum and 550kcal or 2300kJ),
was administered daily, on cycle days 7–14, for 8 days per month.
All patients received dietary counselling.
Concomitant medications
No other dietary supplements were allowed during the study.
Treatment compliance was monitored using nutrition diaries.
Prophylactic antibiotics or leukocyte growth factors were not
routinely prescribed during chemotherapy, but the patients were
allowed to use any medication deemed necessary for appropriate
care of concomitant diseases. Metoclopramide and 5-HT3
inhibitors were used for nausea/vomiting, loperamide for diar-
rhoea, dexpanthenol lozenges 100–200mg t.i.d. for stomatitis, and
pyridoxine 50mg t.i.d. for hand–foot syndrome at the discretion
of the treating physician.
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Patients were scheduled to be evaluated within 21 days prior to
study treatment initiation, 4 weekly during chemo- and radio-
therapy, and at protocol-determined intervals (ranging from 2 to 6
months) posttreatment. At each visit, medical history was taken
and physical examination was performed, which included the
WHO performance status and weight, and the blood cell counts
and serum chemistry were analysed. Blood cell counts were
monitored at 10 to 14-day intervals. Treatment-related adverse
effects were evaluated at every cycle using a diary kept by
the patients and by a physician (PO ¨ or TR). Adverse events
were assessed and graded according to the Common Toxicity
Criteria of the National Cancer Institute of Canada scale version 2.
Number of patients, power assumptions, and statistical
methods
No reliable estimation of L. rhamnosus GG efficacy in reduction of
chemotherapy-associated diarrhoea could be made prior to the
study due to lack of relevant data. The frequency of grades 3 and 4
diarrhoea was the primary variable. Assuming a 50% reduction in
the frequency of grade 3 or 4 diarrhoea from 40–50% to 20–25%,
using 2:1 allocation between the study arms, an 80% power, and a
0.05 significance level, approximately 150 patients need to be
accrued to the study. On the basis of prior data (de Gramont et al,
1997a), patients who receive continuous 5-FU might have less
adverse effects than those treated with bolus 5-FU. A two-group w
2
test at the 0.05 significance level (two-sided) has an 80% power to
detect a difference in the frequency of diarrhoea between the
proportions of 0.60 or 0.40 in the bolus regimen group and
proportions of 0.35 or 0.20 in the continuous 5-FU administration
group, when the respective sample sizes are 62 and 82, also
suggesting that accrual of approximately 150 patients allows
detection of approximately 20% difference in the rate of diarrhoea
between the groups. No interactions between chemotherapy and
nutritional supplements were assumed.
The study was analysed according to the intention-to-treat
principle, and outcome was analysed as defined in the study
protocol. The statistical analyses were performed with a StatView
computer program (SAS institute, Abacus concepts incorporation,
Berkeley, CA, USA). The effects of bolus 5-FU vs continuous 5-FU
regimens, chemoradiation vs chemotherapy only, L. rhamnosus GG
vs no dietary supplements, and guar gum vs no guar gum were
compared using univariate and multivariate logistic regression
models. The results are given as odds ratios with 95% confidence
intervals. Mann–Whitney U-test was used to compare the
treatment groups with respect to quantitative response variables.
Frequency tables were analysed using the w
2 test.
RESULTS
Patient characteristics and compliance
The treatment arms were balanced with gender, the WHO
performance status, primary tumour site, Dukes’ stage, and
radiation therapy given (Table 1). The median age at randomisa-
tion was 60 (range: 31–75); 51% of the participants were men.
Sixteen (11%) subjects did not complete the scheduled 6 months of
adjuvant chemotherapy due to either adverse events (n¼7, six of
whom received bolus 5-FU), cancer recurrence (n¼5), or a
concomitant disease (n¼4). Two patients (both in the continuous
5-FU group) who did not receive any of the study treatments due
to postoperative complications were not included in safety or
efficacy analyses leaving 148 patients for these analyses. None of
the patients were lost to follow-up.
Chemotherapy dose intensity and tolerability
The scheduled 5-FU dose intensity, calculated as the percentage of
the scheduled dose as milligrams of 5-FU given per square metre
per week of the scheduled cumulative dose, was maintained better
among the patients who received the simplified de Gramont
regimen than among those treated with the Mayo regimen (median
93 vs 78%, respectively; Po0.0001).
The simplified de Gramont regimen was tolerated better than
the Mayo regimen (Table 2). Any grade 3 or 4 adverse effect was
present in 87% (65 out of 75) of the patients treated with the Mayo
regimen as compared with only 45% (33 out of 73) of those treated
with the simplified de Gramont regimen, when the vascular access
device (VAD)-related toxicity was included in this analysis
(Po0.0001, Table 2). Vascular access device-related complications
occurred in seven (10%) patients who received continuous 5-FU
infusions; three were classified as serious. The Mayo regimen was
Table 1 Patient characteristics
Entire series Bolus 5-FU/LV Continuous 5-FU/LV Lactobacillus not given Lactobacillus given
N¼150 N¼75 N¼75 N¼52 N¼98
Characteristic n (%) n (%) n (%) n (%) n (%)
Median age (range) 60 (31–75) 61 (35–75) 59 (31–73) 57 (31–75) 61 (35–74)
Gender
Male 76 (51) 39 (52) 37 (49) 25 (48) 51 (52)
Female 74 (49) 36 (48) 38 (51) 27 (52) 47 (48)
Site
Colon 90 (60) 44 (59) 46 (61) 31 (60) 59 (60)
Rectum 60 (40) 31 (41) 29 (39) 21 (40) 39 (40)
Dukes’ stage
B 40 (27) 20 (27) 20 (27) 13 (25) 27 (28)
C 86 (57) 42 (56) 44 (59) 31 (60) 55 (56)
D
a 24 (16) 13 (17) 11 (15) 8 (15) 16 (16)
Rectal radiotherapy
Not given 96 (64) 48 (64) 46 (61) 33 (63) 63 (64)
Given 54 (36) 27 (36) 27 (39) 19 (37) 35 (36)
Abbreviations: 5-FU¼5-fluorouracil; LV¼leucovorin.
aPatients were rendered free from all macroscopic cancer by surgery.
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neutropenia than the simplified de Gramont regimen, whereas
mild-to-moderate hand–foot syndrome was more common among
the patients who received the simplified de Gramont regimen
(Po0.0001). There were no treatment-related deaths.
Lactobacillus supplementation
Forty-nine (51%) of the 97 patients randomly allocated to receive
oral Lactobacillus supplementation and 26 (51%) of the 51 patients
who were allocated to the control group were treated with the
Mayo regimen (P¼0.96). Compliance to Lactobacillus supplemen-
tation was excellent, and all patients consumed their scheduled
doses. The frequency of grade 3–4 diarrhoea was lower among
patients who received Lactobacillus supplements than in the rest of
the patients (22 vs 37%; P¼0.027, Figure 1). Seventy-six (78%)
patients in the Lactobacillus supplementation group and 43 (84%)
in the control group reported diarrhoea of any grade during the
study (tested grade 0 vs 40, P¼0.39). Abdominal discomfort
resulting from flatulence, borborygmia, or abdominal distension
was less in patients who received Lactobacillus supplements (grade
2 or 3 in 2 vs 12%, P¼0.025), and any grade of abdominal
discomfort was present in 57 (59%) of the patients who received
Lactobacillus versus in 38 (75%) of those who did not (P¼0.058).
However, Lactobacillus supplementation had no significant effect
on the overall toxicity of treatment, or the frequency of stomatitis
or neutropenia (Table 2).
None of the patients had Lactobacillus GG growth in blood
bacterial cultures. Nine (10%) patients allocated to receive
Lactobacillus had neutropenic infection as compared to two (4%)
of those who did not receive it (P¼0.24). Eight patients (8%) in
the Lactobacillus group required hospital care for bowel toxicity,
as compared to 11 (22%) in the comparator group (P¼0.021).
Twenty (21%) of the patients who received Lactobacillus
supplementation had chemotherapy-dose reductions due to
bowel toxicity as compared to 24 (47%) among those who did not
receive Lactobacillus (P¼0.0008). Only one patient discontinued
chemotherapy primarily due to bowel toxicity (this patient was
allocated not to receive Lactobacillus supplementation).
Fibre supplementation
Nine (18%) patients discontinued fibre supplementation due to a
taste aversion (these patients were included in the analysis
according to the intention-to-treat principle). Addition of fibre
did not influence the overall gastrointestinal toxicity (P¼0.13).
Guar gum supplementation did not reduce the frequency of severe
diarrhoea as compared to patients who did not receive fibre (25 vs
30%, respectively; P¼0.24). There was no difference between the
allocation groups in the proportions of patients who had
abdominal discomfort resulting from flatulence, borborygmia, or
abdominal distension (grade 2 or 3 in 2 vs 7%, P¼0.24), and the
Table 2 Treatment-related adverse effects
Bolus 5-FU/LV Continuous 5-FU/LV Odds ratio (95% CI) No Lactobacillus Lactobacillus given Odds ratio (95% CI)
N¼75 N¼73 N¼51 N¼97
Adverse effect n (%) n (%) n (%) n (%)
Any
Grade 0–2 10 (13) 40 (55) 0.14 (0.06–0.31) 16 (31) 34 (35) 0.77 (0.35–1.72)
Grade 3–4 65 (87) 33 (45) Po0.0001 35 (69) 63 (65) P¼0.53
Stomatitis
Grade 0–2 32 (43) 64 (88) 0.09 (0.04–0.22) 30 (59) 66 (68) 0.59 (0.26–1.35)
Grade 3–4 43 (57) 9 (12) Po0.0001 21 (41) 31 (32) P¼0.21
Diarrhoea
Grade 0–2 42 (56) 66 (90) 0.11 (0.04–0.29) 32 (63) 76 (78) 0.38 (0.16–0.89)
Grade 3–4 33 (44) 7 (10) Po0.0001 19 (37) 21 (22) P¼0.027
Neutropenia
Grade 0–2 53 (71) 63 (86) 0.38 (0.16–0.90) 43 (84) 73 (75) 2.00 (0.74–4.89)
Grade 3–4 22 (29) 10 (14) P¼0.029 8 (16) 24 (25) P¼0.19
Neutropenic infection
No 67 (89) 70 (96) 0.34 (0.08–1.4) 49 (96) 88 (90) 2.62 (0.53–13)
Yes 8 (11) 3 (4) P¼0.13 2 (4) 9 (10) P¼0.24
Hand–foot syndrome
Grade 0–2 75 (100) 70 (96)  (0.0– 50 (98) 95 (98)  (0.0–
Grade 3 0 (0) 3 (4) P¼0.98 1 (2) 2 (2) P¼0.97
Abbreviations: CI¼confidence interval; 5-FU¼5-fluorouracil; LV¼leucovorin.
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Figure 1 Effect of oral Lactobacillus rhamnosus GG (L) and Lactobacillus
rhamnosus GG plus fibre (guar gum, LþF) supplementation on adverse
events recorded during 5-FU-based chemotherapy.
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srates of chemotherapy-dose reductions due to bowel toxicity were
also similar between the groups (P¼0.20).
DISCUSSION
Chemotherapy-related diarrhoea is a common adverse effect in the
treatment of colorectal cancer, since for example 5-FU, capecita-
bine, and irinotecan administration is frequently associated with
diarrhoea. Severe diarrhoea may lead to nutritional and metabolic
imbalances, and severe neutropenia associated with diarrhoea may
be life threatening. The present findings indicate that the
frequency of grade 3 or 4 diarrhoea may be reduced with the use
of Lactobacillus supplementation. The latter finding is of interest,
since Lactobacillus supplementation appears to have few or no
adverse effects, Lactobacillus capsules are simple to administer,
and they are associated with low costs. Patients who received
Lactobacillus during chemotherapy reported less abdominal
discomfort than those who did not receive it, and these subjects
had also fewer chemotherapy-dose reductions, which might have
an impact on chemotherapy efficacy. As many other bacteria,
lactobacilli may occasionally cause septicaemia in severely
immunocompromised patients (Salminen et al, 2004), but L.
rhamnosus was identified in none of the blood cultures during the
study. There was no difference between the allocation groups in
the frequency of neutropenic fever.
Somewhat unexpectedly, nutritional supplements have not been
evaluated in the prevention and treatment of chemotherapy-
related gastrointestinal adverse effects in controlled studies. In one
study, dosing of Lactobacillus plantarum during 5-FU adminis-
tration improved food intake and helped to maintain the body
weight in rats, but it did not prevent diarrhoea (Von Bultzingslowen
et al, 2003). Instead, probiotics have been studied in a variety
of bowel diseases other than cancer in humans. Lactobacillus
rhamnosus GG has been found to alleviate diarrhoea caused by a
viral infection or Clostridium difficile, and to be useful in the
prevention of traveller’s diarrhoea or diarrhoea related to
administration of antibiotics (Ouwehand et al, 2002; Vaarala,
2003). Probiotics may also reduce radiation therapy-related
diarrhoea (Salminen et al, 1988; Urbancsek et al, 2001; Delia
et al, 2002). The mode of action is not fully understood, but
probiotics are involved in some cytoprotective processes, such as
induction of heat-shock protein expression in intestinal epithelial
cells (Tao et al, 2006), and prevention of cytokine-induced
epithelial cell damage (Yan et al, 2007).
The combination of hydrolysed guar gum fibre and lactobacilli
has been suggested to be effective for diarrhoea (Meier et al, 2003).
One-third of the present patients received this combination, but we
detected no further reduction in gastrointestinal adverse effects
among patients who received the combination. The optimal dose
and schedule to administer fibre are not known. We administered
11g hydrolysed guar gum fibre daily for 8 days per month, but this
dose may have been too low or the intervention duration too short.
We chose not to administer guar gum concomitantly with
chemotherapy to avoid nausea, because some individuals find its
taste aversive.
The simplified de Gramont regimen that includes 5-FU given
both as a bolus and as a 48-h continuous infusion was found to
be better tolerated than the Mayo regimen, where 5-FU is given
as boluses only. Earlier comparisons involving continuous
and protracted 5-FU regimens are in line with present findings
suggesting that the more protracted regimens are generally
associated with less adverse effects (de Gramont et al, 1997a;
Andre et al, 2003; Kohne et al, 2003; Saini et al, 2003). Efficacy
comparisons between the de Gramont regimen or its modifications
and the Mayo regimen suggest that the former are no less effective
(de Gramont et al, 1997a; Andre et al, 2003).
Grade 3 or 4 adverse effects were frequently reported in the
present series; 45% of the patients treated with the simplified de
Gramont regimen and 87% of those treated with the Mayo regimen
had at least one grade 3 or 4 adverse effect. These figures are
higher (Andre et al, 2003) or approximately similar in frequency
(Labianca et al, 1995) as those reported from studies where similar
types of chemotherapy have been administered in the adjuvant
setting. Use of radiation therapy in rectal cancer, and the patients
keeping a diary may have increased the number of reported events
in the present series. We administered 5-FU as true boluses with an
approximate injection time of 3min, which may be associated with
more adverse events than short (about 15min) infusions (Andre
et al, 2001). We also included VAD-related adverse effects, though
they were infrequent in comparison to some other series (Carde
et al, 1989; Gleeson et al, 1993; Kock et al, 1998).
The chemotherapy regimens investigated did not contain
irinotecan, capecitabine, or oxaliplatin that are now commonly
used to treat colorectal cancer, which is a limitation of the study.
The study was not placebo-controlled nor blinded to administra-
tion of the dietary supplements, which may or may not have
influenced assessment of adverse effects. To remedy these potential
shortcomings, we have initiated a prospective, randomised,
multicentre, double blind, placebo-controlled study with a cross-
over design where we investigate the effects of Lactobacillus
supplementation in conjunction with chemotherapy that contains
capecitabine, oxaliplatin, irinotecan, and bevacizumab.
We conclude that daily oral administration of L. rhamnosus GG
may reduce the frequency of severe 5-FU-based chemotherapy-
related diarrhoea, whereas fibre supplementation may be of little
benefit. Lactobacillus supplementation may be a practical and well-
tolerated means to reduce the severity of 5-FU-based chemo-
therapy-induced diarrhoea, and deserves to be evaluated further.
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